Literature DB >> 16024649

Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire.

Rinke Bos1, Suzanne van Duikeren, Thorbald van Hall, Patricia Kaaijk, Richard Taubert, Bruno Kyewski, Ludger Klein, Cornelis J M Melief, Rienk Offringa.   

Abstract

A variety of antigens that display a highly tissue-specific expression pattern have recently found to be also expressed in medullary thymic epithelial cells (mTEC). This unique feature of mTEC plays an important role in preventing hazardous autoimmune responses through thymic tolerization of T-cell subsets directed against autoantigens but could also limit the possibility of exploiting tumor-associated antigens for immune-mediated targeting of cancers. Our present study shows that expression of carcinoembryonic antigen (CEA) in thymic epithelial cells of CEA-transgenic mice results in tolerization of a major fraction of the CD4+ T-cell repertoire against this antigen, thereby markedly limiting the effect of CEA-specific immunization against CEA-overexpressing tumors. The expression of CEA in mTEC of CEA-transgenic mice is mirrored by its expression in human mTEC, arguing that promiscuous gene expression in these thymic stromal cells needs to be considered as a potential hurdle for immunotherapies of cancer that target tissue-specific autoantigens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024649     DOI: 10.1158/0008-5472.CAN-05-0666

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Thymic stromal cell subsets for T cell development.

Authors:  Takeshi Nitta; Harumi Suzuki
Journal:  Cell Mol Life Sci       Date:  2016-01-29       Impact factor: 9.261

2.  Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.

Authors:  Lucia Poncette; Xiaojing Chen; Felix Km Lorenz; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

3.  Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.

Authors:  Elizabeth K Wansley; Mala Chakraborty; Kenneth W Hance; Michael B Bernstein; Amanda L Boehm; Zhimin Guo; Deborah Quick; Alex Franzusoff; John W Greiner; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

4.  Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.

Authors:  Sean O Ryan; Michael S Turner; Jean Gariépy; Olivera J Finn
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

5.  Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen.

Authors:  Luigi Aurisicchio; Giuseppe Roscilli; Emanuele Marra; Laura Luberto; Rita Mancini; Nicola La Monica; Gennaro Ciliberto
Journal:  Hum Gene Ther       Date:  2015-06       Impact factor: 5.695

Review 6.  Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.

Authors:  Chung-Han Lee; Roman Yelensky; Karin Jooss; Timothy A Chan
Journal:  Trends Immunol       Date:  2018-05-08       Impact factor: 16.687

7.  Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.

Authors:  Lavakumar Karyampudi; Christopher J Krco; Kimberly R Kalli; Courtney L Erskine; Lynn C Hartmann; Karin Goodman; James N Ingle; Matthew J Maurer; Aziza Nassar; Chao Yu; Mary L Disis; Peter J Wettstein; John D Fikes; Melanie Beebe; Glenn Ishioka; Keith L Knutson
Journal:  Cancer Immunol Immunother       Date:  2009-07-21       Impact factor: 6.968

Review 8.  The "A, B and C" of Her-2 DNA vaccine development.

Authors:  Wei-Zen Wei; Jennifer Jacob; Olga Radkevich-Brown; Paula Whittington; Yi-chi M Kong
Journal:  Cancer Immunol Immunother       Date:  2008-02-14       Impact factor: 6.968

Review 9.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

10.  Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.

Authors:  Adam E Snook; Benjamin J Stafford; Peng Li; Gene Tan; Lan Huang; Ruth Birbe; Stephanie Schulz; Matthias J Schnell; Mathew Thakur; Jay L Rothstein; Laurence C Eisenlohr; Scott A Waldman
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.